What I Read This Week...
Drug companies race to fix muscle mass loss caused by Ozempic, doctors discover a new cause for women's autoimmune conditions, and Adam Neumann tries to buy back WeWork
Caught My Eye…
Drug companies, nutrition startups and gyms are racing to offer solutions to muscle mass loss caused by weight-loss drugs like Ozempic. While GLP-1s, the current class of weight-loss drugs offered by companies like Novo Nordisk, can help patients rapidly lose weight and steer off cravings, much of this weight loss is often in the form of lean muscle mass which risks accelerating frailty in older patients. While drug companies are trying to develop solutions to this issue, doctors are recommending two simple fixes: eat more protein and lift weights.
Scientists have been trying to understand why women are more susceptible to autoimmune conditions, a type of disease where your immune system mistakenly attacks your own body. According to a recent study, this may be due to a special set of molecules that act on the extra X chromosome that only women carry. These molecules can sometime confuse the immune system, which may explain why women are more susceptible to autoimmune conditions like lupus and multiple sclerosis. If correct, this could pave the way for a new set of treatments that work specifically on these molecules instead of the current cohort of drugs which blunt the entire immune system.
Adam Neumann, co-founder and CEO of bankrupt real-estate company WeWork, is in preliminary discussions with hedge fund Third Point to buy back the company out of bankruptcy. WeWork, the office-sharing company once valued at $47Bn, filed for bankruptcy in November last year as the company’s debt-fueled growth in real-estate assets came up against a collapse in demand for office space.
Subscribe to receive weekly reading lists, quick essays and deep dives into critical themes
The Vladimir Putin Interview (Tucker Carlson)
Can AI Unlock the Secrets of the Ancient World? (Bloomberg)